George Orphanides is the Chief Scientific Officer at LifeArc. George has over 26 years of experience in the pharmaceutical and biotech industry, working at the forefront of new treatments for cancer and rare diseases.
Most recently, he served as Chief Scientific Officer at invoX Pharma, where he led a portfolio of four immuno-oncology programmes in clinical development, alongside preclinical projects in oncology and respiratory disease. George has also spent several years working at the intersection of industry, academia, and the charitable sector. He co-founded and delivered an oncology accelerator in collaboration with Cancer Research UK and Innovate UK, supporting the launch and growth of multiple start-ups.
He has also served on the boards of companies focused on oncology, vaccines, and rare diseases. Prior to this, George held several senior leadership roles at AstraZeneca, where he led cross-functional teams and strategic collaborations to accelerate oncology innovation.
